Study on serum CXCL6 as a diagnostic and progression marker for idiopathic pulmonary fibrosis and its related mechanisms

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400084292

Enrollment

Unknown

Registered

2024-05-14

Start date

2024-05-20

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic pulmonary fibrosis

Interventions

IPF:None

Normal:None

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? All IPF patients meet the diagnostic criteria for idiopathic pulmonary fibrosis established by the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) in 2018; ? The patient did not have any concurrent tumors, such as lung cancerous lesions or lung malignant tumors; ? The patient did not use glucocorticoids within the month prior to inclusion in the experiment

Exclusion criteria

Exclusion criteria: ? Concomitant pulmonary infections, allergic pneumonia, and other respiratory system diseases; ? Concomitant or previous radiation pneumonia, sarcoidosis, and pneumoconiosis; ? Pulmonary lesions caused by occupation, medication, environment, heart failure, etc; ? Serious diseases such as hypertension, heart disease, liver dysfunction, and renal dysfunction; ? The patient is in pregnancy or lactation period

Design outcomes

Primary

Measure	Time frame
CXCL6;	—

Secondary

Measure	Time frame
Pulmonary function;6 minutes walk test;Pulmonary artery pressure;	—

Countries

China

Contacts

Public ContactQing Liang

Shanghai Fifth People’s Hospital, Fudan University

liangqing@5thhospital.com+86 188 1756 0377

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026